	US 12,103,971 B2
	HIV specific binding molecules
Marcin Dembek, Abingdon (GB); Luis Filipe Da Silva Godinho, Abingdon (GB); Praveen Singh, Abingdon (GB); Emma Elizabeth Baston, Abingdon (GB); Andrew Creese, Abingdon (GB); Thomas Minshull, Abingdon (GB); and Pranav Bheamadu, Abingdon (GB)
Assigned to IMMUNOCORE LIMITED, Abingdon (GB)
Filed by Immunocore Limited, Abingdon (GB)
Filed on Oct. 5, 2022, as Appl. No. 17/938,321.
Claims priority of provisional application 63/312,077, filed on Feb. 20, 2022.
Prior Publication US 2023/0265191 A1, Aug. 24, 2023
Int. Cl. C07K 16/28 (2006.01); A61K 47/64 (2017.01); A61P 31/18 (2006.01); C07K 14/725 (2006.01); A61K 38/00 (2006.01)

CPC C07K 16/2809 (2013.01) [A61K 47/6425 (2017.08); A61P 31/18 (2018.01); C07K 14/7051 (2013.01); A61K 38/00 (2013.01); C07K 2317/92 (2013.01); C07K 2317/94 (2013.01)]

16 Claims

1. A specific binding molecule having the property of binding to SLYNTVATL (SEQ ID NO: 1) in complex with HLA-A*02 and comprising a TCR alpha chain variable domain and a TCR beta chain variable domain,

wherein the alpha chain variable domain comprises an amino acid sequence selected from:

	a)
	(SEQ ID NO: 2)
	AKEVEQNSGP LSVPEGAIAS LNCTYSSWEG QSFFWYRQYS

	GKSPELIMKL YADPDKEDGR FTAQLNKASQ YVSLLIRDSQ

	PSDSATYLCA VRTNSGYALN FGKGTSLLVT P;

	b)
	(SEQ ID NO: 3)
	AKEVEQNSGP LSVPEGAIAS LNCTYSSWEG QSFFWYRQYS

	GKSPELIMFL YADPDKEDGR FTAQLNKASQ YVSLLIRDSQ

	PSDSATYLCA VRTNAGYALN FGKGTSLLVT P;
	and

	c)
	(SEQ ID NO: 4)
	AKEVEQNSGP LSVPEGAIAS LNCTYSSWEG QSFFWYRQYS

	GKSPELIMKL YADPDKEDGR FTAQLNKASQ YVSLLIRDSQ

	PSDSATYLCA VRTNAGYALN FGKGTSLLVT P;

optionally with an N-terminal methionine (SEQ ID NOs: 41-43), and

the beta chain variable domain comprises the amino acid sequence:

	(SEQ ID NO: 5)
	DAGVTQSPTH LIKTRGQQVT LRCSPKSGHD TVSWYQQALG

	QGPQFIFQAV RGVERQRGNF PDRFSGHQFP NYSSELNVNA

	LLLGDSALYL CASSDTVSYE QYFGPGTRLT VT,

optionally with an N-terminal methionine (SEQ ID NO: 44).